20-F/A: BGM Group Ltd. Amends Annual Report Following SEC Comments, Revenue Declines Sharply

BGM Group Ltd. files an amendment to its annual report to address SEC comments and reports a significant decrease in revenue from heparin products and sausage casings.

Summary

• BGM Group Ltd. has filed Amendment No. 3 to its annual report on Form 20-F/A to address comments from the SEC.
• The amendment restates sections related to business overview and operating results for the fiscal year ended September 30, 2024.
• Sales from heparin products and sausage casings decreased by $13.1 million, or 85%, from $15.3 million in 2023 to $2.2 million in 2024.
• The decline in heparin product sales is attributed to centralized procurement policies, price decreases, customer inventory, and the shutdown of a production facility.
• The company shut down the production factory of Chengdu Qilianshan Biotechnology Co., Ltd., which occupied 78% of the company's total Heparin products to reduce losses.
• Sausage casing sales decreased due to the impact of the national centralized procurement policy.
• The company is relocating its production facility to Chongqing to reduce costs and improve efficiency.
• Chongqing Shengfu Biological Technology Co., Ltd. initiated trial production in October 2024 and is currently under regular production operations.
• The company believes its current facilities are adequate but may seek additional space for future growth.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant decrease in revenue and the shutdown of a production facility. While the company is taking steps to address these issues, the current financial performance is concerning.

Positives

• The company is relocating its production facility to Chongqing to reduce production costs, improve operational efficiency, and leverage geographical and resource advantages.
• Chongqing Shengfu Biological Technology Co., Ltd. initiated trial production in October 2024 and is currently under regular production operations, which coincides with the emerging recovery of the heparin industry.
• The company believes its current facilities are adequate and suitable for their operations.

Negatives

• Sales from heparin products and sausage casings decreased significantly by $13.1 million, or 85%.
• Heparin product sales decreased by $10 million due to centralized procurement policies, price decreases, and customer inventory.
• The company shut down the production factory of Chengdu Qilianshan Biotechnology Co., Ltd., which occupied 78% of the company's total Heparin products to reduce losses.
• Sausage casing sales decreased by $2 million due to the national centralized procurement policy.

Risks

• The centralized procurement policy for heparin products in hospitals has significantly reduced procurement prices.
• The price of heparin products has been on a downward trend.
• Customers had a relatively large inventory of heparin products, leading to decreased procurement.
• The company's production area of Chengdu Qilianshan Biotechnology Co., Ltd. was situated within the urban renewal area of the Qionglai Green Food Industrial Functional Zone, requiring relocation.

Future Outlook

The company is relocating its production facility to Chongqing to reduce costs and improve efficiency, and Chongqing Shengfu Biological Technology Co., Ltd. initiated trial production in October 2024 and is currently under regular production operations, which coincides with the emerging recovery of the heparin industry. The company believes its current facilities are adequate but may seek additional space for future growth.

Industry Context

The document highlights the impact of centralized procurement policies on the pharmaceutical industry, particularly affecting the pricing and sales volume of heparin products. This trend is indicative of increased government intervention in healthcare procurement to control costs, which can significantly impact pharmaceutical companies' revenue and profitability.

Comparison to Industry Standards

• It is difficult to compare BGM Group's performance directly to industry standards without knowing the specific market segments they operate in and the performance of their direct competitors.
• However, the document mentions the impact of centralized procurement policies on heparin products, which is a common challenge faced by pharmaceutical companies in China.
• Companies like Hepalink, a major player in the heparin market, may face similar pressures from centralized procurement and price reductions.
• The relocation of the production facility to Chongqing to leverage tax incentives and resource advantages is a strategy employed by many companies to optimize costs and improve competitiveness.

Stakeholder Impact

• Shareholders may be concerned about the significant decrease in revenue and the impact on the company's profitability.
• Employees may be affected by the shutdown of the production facility and the relocation of operations.
• Customers may experience changes in product availability and pricing due to the centralized procurement policies and production changes.
• Suppliers may be impacted by changes in production volume and the relocation of the production facility.

Next Steps

• Continue regular production operations at Chongqing Shengfu Biological Technology Co., Ltd.
• Monitor the recovery of the heparin industry.
• Seek additional space as needed to accommodate future growth.

Key Dates

Keywords

BGM Group Ltd, Heparin, Sausage Casings, Revenue, Amendment, SEC, Production, Relocation, Procurement, Financial Results